I cannot provide instructions for taking Zepbound based on the evidence provided, as none of the studies or guidelines in the evidence base contain information about Zepbound (tirzepatide) administration instructions.
The evidence provided consists primarily of tuberculosis treatment guidelines from 2003 1, pediatric midazolam dosing 2, and studies about ziprasidone 3, 4, 5 and Z-drugs 6. While one study mentions tirzepatide for obesity treatment in type 2 diabetes 7, it does not provide prescribing or administration instructions.
What You Need
For accurate Zepbound (tirzepatide) administration instructions, you must consult:
- The FDA-approved prescribing information/drug label for Zepbound
- Official manufacturer instructions from Eli Lilly
- Current endocrinology or obesity medicine guidelines that specifically address tirzepatide
General Context from Available Evidence
The only relevant information is that tirzepatide was studied as a once-weekly subcutaneous injection at doses of 10 mg and 15 mg for weight management in adults with obesity and type 2 diabetes 7. However, this research study does not provide the detailed administration technique, injection site rotation, storage requirements, or other practical instructions needed for safe medication use.
You should obtain the official Zepbound prescribing information before administering this medication.